PROJEKTI
   

Project
Acronym: IBD-BIOM 
Name: Diagnostic and prognostic biomarkers for inflammatory bowel disease 
[ | CORDIS URL]
Project status: From: 2012-10-01 To: 2016-09-30 (Completed)
Contract number: 305479  
Action line: FP7-HEALTH 
Type (Programme): FP7 
Funding scheme: STREP 
Project cost: 7.857.242,00 EUR
Project funding: 5.999.611,00 EUR
Project coordinator
Organisation Name: THE UNIVERSITY OF EDINBURGH 
Organisation adress:  
Organisation country: Velika Britanija 
Contact person name:  
Contact person email:  
Croatian partner
Organisation name: Prirodoslovno-matematički fakultet 
Organisation address:  
Contact person name: Vlatka ZOLDOS
Contact person tel:
  Contact person fax:  
Contact person e-mail:  
Partners
Organisation nameCountry
Short description of project
Inflammatory bowel diseases affect 0.8% of the Europeans, and are associated with high morbidity, definite mortality and an increasing economic burden. Current diagnostic tools and therapeutics for IBD are unsatisfactory. Development of biomarkers allowing insights into pathogenesis, prognosis and targeted therapy is a major unmet need. This programme addresses that need. IBD-BIOM is a multidisciplinary consortium of leading academic and industrial SME researchers in inflammatory bowel disease, genomics, glycomics, glycoproteomics and activomics. Recent genome-wide association studies performed by IBD-BIOM partners have identified nearly 100 genes associated with IBD, but clinical application of these is so far limited. IBD-BIOM will capitalise on its existing high quality clinical, genetic, biochemical and immunological data and biological samples on over 6000 very well characterised IBD patients and controls by exploiting novel technological approaches made available through the expertise and global leading position of IBD-BIOM partners. These comprise cutting edge epigenetic, glycomic, glycoproteomic and activomic approaches which were all previously reported to be associated with inflammation and disturbances to the immune system. The inclusion of these complementary analyses in the diagnostics of IBD should also facilitate elucidation of pathways through which environmental exposures influence IBD risk and progression. A complex system’s biology approach will be used to integrate, interrogate and understand this multidimensional dataset to identify novel early diagnostic and prognostic biomarkers and new targets for therapeutic intervention. The track record of achievement of IBD-BIOM partners coupled to the central and leading positions of the research-intensive SME partners in IBD-BIOM is a strong indication that the ambitions work programme will be achieved and a framework to facilitate swift conversion of research discoveries into commercial products.  
Short description of the task performed by Croatian partner
 


   

 


Design by: M. Mačinković

(C)opyright by Sveučilište u Zagrebu,